A B S T R A C T Lysozyme turnover studies with Ilabeled human lysozyme were carried out on 22 patients, viz. nine control patients, seven nephrological patients with varying degrees of renal insufficiency, including three bilaterally nephrectomized patients, and six hematological patients with disturbed turnover of the neutrophilic granulocytes.
INTRODUCTION
Lysozyme (muramidase) exists, among the cells of the blood, exclusively in neutrophilic granulocytes and monocytes (1) (2) , whereas in the tissues the greatest concentrations are found in the bone marrow, lungs, intestines, spleen, and kidneys (3) (4) (5) (6) . Plasma lysozyme is believed to stem mainly from disintegrating neutrophilic granulocytes (7) (8) (9) , and the high concentrations in bone marrow, lung, spleen, and intestine have been suggested to be due to the presence and probable break- down of neutrophilic granulocytes in these organs (6) . Previous turnover studies in the rat have demonstrated that the high lysozyme concentration in the kidney reflects the catabolism of lysozyme in that organ (6) ; lysozyme is believed to be filtered in the glomeruli, and reabsorbed in the proximal tubules, where probably also the breakdown of the lysozyme molecule takes place. This provides the basis for the application of lysozyme determinations in blood and urine as diagnostic tools in hematology and nephrology, where lysozyme measurements have been of value in the assessment of states with disturbed granulocyte turnover and in patients with proximal tubular defects.
The aim of the present study was to obtain quantitative data concerning plasma lysozyme turnover in normal man using 'I-labeled human lysozyme, and, in addition to study lysozyme turnover in patients with two groups of diseases known to increase plasma lysozyme concentration, viz. hematological disorders with disturbed turnover of neutrophilic granulocytes and renal disorders with reduced glomerular filtration rate. Furthermore, turnover studies were carried out on three bilaterally nephrectomized patients in order to investigate the importance of possible extrarenal factors in lysozyme catabolism.
METHODS
Patients. 22 patients were studied. Relevant clinical data on these patients are summarized in Table I . Nine patients constitute the control group, fulfilling the following criteria: normal hemoglobin concentration, leukocyte, differential, and thrombocyte counts, serum creatinine below 1.3 mg/100 ml and endogenous creatinine clearance above 65 ml/min, normal urinary sediment, and normal concentrations of lysozyme in plasma and urine. Seven patients had renal disease with reduced glomerular filtration rate, including three bilaterally nephrectomized patients; six patients had hematological diseases with increased lysozyme concentration. Before the study, the purpose and the procedures were explained to the patients and their consent obtained. Enzymatic actizity. Purified human lysozyme was kindly provided by Professor E. F. Osserman, Columbia University, New York. This lysozyme was isolated from the urine of patients with monocytic and myelomonocytic leukemia by bentonite adsorption and elution with 5% aqueous pyridine (10) and has been shown to be identical with normal human plasma lysozyme (11) . The enzyme was crystallizable (10), and no impurities or signs of denaturation in this preparation could be demonstrated by electrophoresis, immunoelectrophoresis, acrylamide gel analysis, or ultracentrifugation (11); in fact, the lysozyme preparation may be considered more than 99% pure. ' The study was conducted over a 3 month period; during that time the labeled protein was kept in a phosphate buffer ' Osserman, E. F. Personal communication.
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(pH 7.5) at a concentration of 6.2 mg/ml at 4VC. At the end of the study period the lytic properties of the enzyme were as before the study; also, the fractional catabolic rates of the patients with normal renal function did not vary with the time of the study, thus militating against denaturation during the storing of the labeled protein.
Lysozyme activity in plasma (with EDTA as anticoagulant) and in urine was measured by the lysoplate method of Osserman and Lawlor (11) with human lysozyme as a reference standard. Measurements were carried out in duplicate.
Labeling procedure. The human lysozyme was labeled with 'II at New England Nuclear Corp., Boston, Mass.
by a modified chloramine-T method as described by McConahey and Dixon (12) . Although the chloramine-T method as described by Greenwood, Hunter, and Glover (13) During the period of study daily measurements of plasma and urinary lysozyme concentrations and of 24-hr endogenous creatinine clearance were carried out. These parameters, as well as the body weight remained constant in all patients with intact kidneys. In the nephrectomized patients plasma creatinine concentration rose during the study period, whereas the other parameters, including plasma lysozyme concentration, remained constant. None of the patients had fever during the study period.
The thyroid gland was blocked with 52 mg potassium iodine given daily for a 7 day period, the nephrectomized patients for a 14 day period.
The plasma volume was determined with Evans blue (14) .
Methods of calculation. In all the patient examined turnover data were calculated on the basis of the plasma disappearance curve using the "peel-off" technique described by Nosslin (15) . The plasma curves were construed by taking the injected dose divided by the plasma volume as 100% activity, and plotting the activity on semilogarithmic paper. The individual plasma disappearance curves were divided in a series of exponential functions, each expressed by intercept (ci) and slope (b1). From In addition to this method of calculation, turnover data were calculated also by the "metabolic clearance method" (16) . This method which is based upon the clearance concept is independent of the peel-off technique since it employs only the final slope of the plasma disappearance curve plus the radioiodine excreted in the urine. In this calculation the results of the first 1 or 2 days are disregarded thereby eliminating from the calculation possibly denatured protein which is quickly catabolized. where Xu = daily excretion of radioiodine in the urine, expressed as a fraction of the administered dose; Xp=frac-tion of the administered dose of radioiodine remaining in the intravascular pool; and N=number of days. The fractional catabolic rate thus derived (kc) was then corrected by using the following formula: ken = kc I1-) (per hour), where ke = the "true" fractional catabolic rate (see below); 8 = the constant of the final slope of the plasma disappearance curve; and k. = 0.0625 (per hour).
Abbreviations used in this paper: FCR, fractional catabolic rate. This correction is made because the radioiodine liberated by breakdown of the labeled protein is not excreted immediately but is distributed within an iodine pool equal to one-third of the body weight and subsequently excreted with a rate constant (k.) of about 0.0625/hr (17) . This method is applicable to patients with normal renal function and was applied to those control and hematological patients in whom urinary collection was sufficient (11 patients, see Tables III and V) .
The renal lysozyme filtration rate expressed as per cent of the glomerular filtration rate (as measured with the endogenous creatinine clearance method) was calculated for 
RESULTS
In all the patients examined, a two-phase plasma disappearance curve with a "final" straight slope was obtained. Fig. 1 shows the plasma disappearance curves from the nine control patients. The turnover data calculated on the basis of these plasma disappearance curves are summarized in Table III. This table also shows the FCR calculated with the metabolic clearance method and the renal lysozyme filtration rate as per cent of the endogenous creatinine clearance. Fig. 2 shows the plasma disappearance curves from the three nephrectomized patients. Fig. 3 is a magnification of the composite plasma curves from the nephrectomized and control patients during the first 200 min after injection. This clearly demonstrates the importance of the kidneys in the removal of plasma lysozyme also during the initial phase after injection, since a difference between the two curves is discernible already at the first sampling after 5 min.
Figs. 4 and 5 demonstrate the plasma disappearance curves from the patients with renal insufficiency and from the patients with hematological disorders. Turnover data from these curves are shown in Tables IV  and V was shown that the increased plasma lysozyme concentration found in severe uremia is due to diminished glomerular filtration whereas the high plasma levels found in certain hematological disorders with disturbed neutrophil turnover is due to increased production of plasma lysozyme probably through release of enzyme from disintegrating cells. The importance of the kidney for the degradation of plasma lysozyme has been shown in both experimental and clinical studies (4, 6, (19) (20) (21) (22) (23) (24) (25) although the quantitative relationship between lysozyme turnover and kidney function has not been documented previously.
Our finding that lysozyme can be degraded by extrarenal mechanisms is a counterpart in the human to the demonstration of Balazs and Roepke (20) in the rat. These workers found linearly rising plasma lysozyme concentrations immediately after bilateral nephrectomy but after 24 hr plasma levels were lower than would be expected on the basis of the initial values. In addition to the demonstration in this work that labeled enzyme is catabolized in anephric man, extrarenal sites of catabolism were suggested by the finding that plasma lysozyme concentration remained constant in the nephrectomized patient during the study period; this would be possible only if extrarenal sites existed. Three possible interpretations should be considered: (a) extrarenal factors always contribute to the breakdown of lysozyme with a FCR of about 15% of the total FCR found in persons with intact kidney function, (b) extrarenal lysozyme catabolism is a function of the uremic state, or (c) with rising plasma lysozyme levels (no matter whether due to increased production or decreased destruction) new extrarenal pathways of catabolism are opened. The first explanation appears the most likely. A priori, it seems probable that lysozyme is subjected to the same (admittedly unknown) mechanisms of random destruction as other proteins (e.g. albumin). Besides, it is difficult to comprehend how the uremic state could induce new pathways for destruction of lysozyme since it has been shown that at least the albumin turnover rate is decreased or normal in uremic patients (26) . Also, if lysozyme breakdown in the nephrectomized patient should be dependent upon the uremic state it might be expected that lysozyme catabolism was accelerated during the period of study between two hemodialyses when uremia increased. The lysozyme turnover rate was, however, constant. The possibility that rising levels of plasma lysozyme should induce new pathways of destruction is not compatible with the demonstration that hematological patients with plasma lysozyme concentrations as high as those found N. E. Hansen, H. Karle, V. Andersen, and K. 0lgaard in patients with severe uremia had FCRs as expected from their creatinine clearance values. Thus, although no conclusive evidence can be presented, we consider it most likely that extrarenal sites for the destruction of lysozyme exist even in normal conditions. As no human lysozyme turnover studies have been published previously it is difficult to evaluate the quantitative turnover data reported in this study. However, in a study of four patients with the adult Fanconi syndrome, where the function of the proximal tubules is severely impaired and consequently a large part of the filtered lysozyme is excreted in the urine, Harrison, Lunt, Scott and Blainey (22) found a lysozyme clearance of 28% of that of creatinine clearance (range 18-49%). This figure would probably give a minimum estimate of lysozyme filtration since it would assume that no filtered lysozyme is reabsorbed in the proximal tubules. In the present study lysozyme filtration by the kidneys as percent of the endogenous creatinine clearance was 34.8% (SD 6.9), in the control group of patients. In the dog, Harrison and Barnes measured the lysozyme filtration to be 38% of that of creatinine clearance (23) .
Although comparisons between turnover data from the different groups of patients of this study may be quite informative, correct turnover data in absolute terms are dependent on the use of undenatured protein, when calculations are based upon analysis of the plasma disappearance curve only. The initial, extremely rapid disappearance of labeled lysozyme from the circulation might be taken to suggest partial denaturation since it it well known that the RES avidly takes up denatured protein. Although denaturation could not be demonstrated by the in vitro and in vivo methods described above, and although apparently our data seem to fit in well with previous data, we felt obliged to apply another method of calculation in addition to the peeloff technique which is based solely on analysis of the plasma disappearance curve. The metabolic clearance method is based on the clearance concept and is independent of the peel-off technique since the metabolic clearance is determined from the ratio urine/plasma of radioiodine, disregarding the first 1 or 2 days, as described in Methods. Thus, if the initial rapid disappearance of labeled lysozyme were due to denaturation the radioiodine liberated in that process would expectedly be excreted within the first 1 or 2 days and consequently not influence the FCR obtained with the clearance method. Consequently, if the initial rapid disappearance of labeled lysozyme were due to denaturation the clearance method would yield lower FCRs than the peel-off technique. Taking together all patients examined with the two methods (Tables III and V) (15) is applied on the present material.
Evidence has been presented that plasma lysozyme mainly stems from disintegrating neutrophilic granulocytes (7) (8) (9) . Well in line with this is the demonstration of the present study that the rate of synthesis in the hematological patients was higher than for the remaining patients, and that the high plasma lysozyme concentration was due to increased production rate whereas the fractional catabolic rate was normal. As further evidence that plasma lysozyme stems from disintegrating neutrophils, the mean content per cell of lysozyme as calculated from the present turnover data may be compared to figures from the literature where intracellular lysozyme concentrations have been reported at 1-6.3 og/1 million leukocytes and 7.2 Ag/1 million neutrophils (27) (28) (29) (30) . In a preliminary study we have, in 13 normal persons, found an intracellular lysozyme content of 7.6±2.1 (SD) Ag/1 million neutro-phils.' Using the mean figure for lysozyme synthesis in the control group of patients (287 pg/kg per hr) and figures from the literature for the neutrophil turnover rate (mean 68 X 106 cells/kg per hr, with 95% limits at 21-142 X 106) (31) a mean content of 4 Ag/ 1 million neutrophils is arrived at (range 2.0-13.7). Figures calculated from this study are thus of the same order of magnitude as the experimentally determined figures of others and ourselves. It should be emphasized that it is a basic assumption for such a calculation that all disintegrating neutrophils liberate their lysozyme content to the plasma.
Somewhat surprisingly, this study demonstrated that the rate of synthesis varied with the creatinine clearance. If it is accepted that plasma lysozyme stems from disintegrating neutrophils this would mean that in uremia either the lysozyme content of the neutrophilic granulocytes is diminished or that the neutrophil turnover rate (number of cells disintegrating per unit time) is decreased. Preliminary studies on the intracellular lysozyme content in neutrophilic granulocytes have shown that neutrophils from severely uremic patients contain significantly lower lysozyme concentrations than normals (mean lysozyme concentration in seven uremic patients 5.2±+1.0 (SD) 1Ag/1 million neutrophils, and in 13 normals 7.6+2.1 (SD) izg/1 million neutrophils; P. less than 0.025). ' 
